Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits | REUTERS

Key Concepts:

• Merger and Acquisition (M&A) in the pharmaceutical industry
• Obesity drug market
• Antitrust risks
• Bidding war
• Pipeline development
• Peak sales projections

FISA Acquires Metser in $10 Billion Deal, Outbidding Novo Nordisk

US drug maker FISA has successfully acquired obesity drug developer Metser for $10 billion, concluding a bidding war with Danish rival Novo Nordisk. Novo Nordisk announced its withdrawal from the race on Saturday, stating it would exit the competition. Metser accepted a revised offer from FISA late on Friday.

Metser's Rationale for Accepting FISA's Offer

Metser cited US antitrust risks associated with Novo Nordisk's bid as the primary reason for accepting FISA's sweetened offer. Previously, Metser had considered Novo Nordisk's bid superior. Novo Nordisk, in its statement, maintained that it believed its offer structure was compliant with antitrust laws.

Market Implications and Strategic Significance

This acquisition grants FISA a significant entry into the highly lucrative obesity drug market. Metser's drugs are projected to achieve peak sales of $5 billion. Although Metser's treatments are still several years away from market launch, this acquisition represents a strategic win for FISA.

Impact on Novo Nordisk and Future Strategy

The acquisition is a setback for Novo Nordisk, which is actively seeking to regain market share against its US competitor, Eli Lilly. In response, Novo Nordisk stated that it is advancing its own pipeline of obesity treatment options and will continue to evaluate opportunities for business development and acquisitions.

Merger Timeline

FISA anticipates closing the merger shortly after Metser's shareholder meeting scheduled for November 13th.

Conclusion

The $10 billion acquisition of Metser by FISA highlights the intense competition and strategic importance of the obesity drug market. FISA's successful bid, despite potential antitrust concerns raised by Metser regarding Novo Nordisk's offer, secures a promising future pipeline for the company. Novo Nordisk, while exiting this particular deal, remains committed to developing its own obesity treatments and pursuing other strategic opportunities.